eCite Digital Repository

Association of apatinib and breast cancer: A systematic review and meta-analysis

Citation

Wang, H and Su, W and Lowe, S and Zhou, Z and Bentley, R and Zhou, Q and Cheng, C and Guo, X and Song, Q and Liang, Q and Li, N and Liang, M and Zhu, Y and Sun, C, Association of apatinib and breast cancer: A systematic review and meta-analysis, Surgical Oncology, 44 Article 101818. ISSN 0960-7404 (2022) [Refereed Article]

Copyright Statement

Copyright 2022 Elsevier Ltd.

DOI: doi:10.1016/j.suronc.2022.101818

Abstract

Background: Breast cancer (BC) is a common malignant tumor. Apatinib in combination with other treatments has been used for BC; however, its safety and efficacy are not well-known. Therefore, this meta-analysis was performed to assess the efficacy and safety of apatinib in the treatment of BC.

Methods:Studies comparing the effects of apatinib-based therapy versus control among BC patients were included. On January 21, 2022, a systematic search was performed in 9 databases. The risk ratio (RR) with 95% confidence interval (CI) was used to estimate efficacy and safety. The I square value (I2) was used to assess heterogeneity. A leave-one-out sensitivity analysis was also conducted. Publication bias was assessed by funnel plots and Egger's and Begg's tests.

Results: A total of 31 studies including 2,258 BC patients were included. The results showed that apatinib group had a significant improvement in disease control rate (DCR, RR = 1.43, 95% CI = 1.35-1.52, I2 = 43.8%) and objective response rate (ORR, RR = 1.79, 95% CI = 1.51-2.13, I2 = 61.8%) compared to the control group. Except for hemorrhage, hypertension, and hand-foot syndrome, the adverse events were similar between apatinib group and control group. Subgroup analyses found statistically significant differences in DCR in all subgroups except for apatinib combined with radiation therapy and with paclitaxel liposome plus S1. For ORR, there were statistically significant differences in all subgroups except for the radiation therapy, and apatinib monotherapy subgroups.

Conclusions: Our study shown apatinib showed good efficacy and acceptable safety in the treatment of BC patients. More high-quality randomized controlled trials from different regions and countries are needed to confirm our findings.

Item Details

Item Type:Refereed Article
Keywords:apatinib, breast cancer, meta-analysis
Research Division:Biomedical and Clinical Sciences
Research Group:Oncology and carcinogenesis
Research Field:Cancer therapy (excl. chemotherapy and radiation therapy)
Objective Division:Health
Objective Group:Clinical health
Objective Field:Treatment of human diseases and conditions
UTAS Author:Zhou, Z (Dr Zhen Zhou)
ID Code:152884
Year Published:2022
Deposited By:Menzies Institute for Medical Research
Deposited On:2022-08-25
Last Modified:2022-10-31
Downloads:0

Repository Staff Only: item control page